BenevolentAI SA
BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, a… Read more
BenevolentAI SA (BAI) - Net Assets
Latest net assets as of December 2023: €94.27 Million EUR
Based on the latest financial reports, BenevolentAI SA (BAI) has net assets worth €94.27 Million EUR as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€123.83 Million) and total liabilities (€29.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €94.27 Million |
| % of Total Assets | 76.13% |
| Annual Growth Rate | 3.31% |
| 5-Year Change | -24.9% |
| 10-Year Change | N/A |
| Growth Volatility | 71.47 |
BenevolentAI SA - Net Assets Trend (2018–2023)
This chart illustrates how BenevolentAI SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BenevolentAI SA (2018–2023)
The table below shows the annual net assets of BenevolentAI SA from 2018 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €94.27 Million | -38.78% |
| 2022-12-31 | €154.00 Million | +144.71% |
| 2021-12-31 | €62.93 Million | -48.68% |
| 2020-12-31 | €122.63 Million | -2.31% |
| 2019-12-31 | €125.52 Million | +56.68% |
| 2018-12-31 | €80.11 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BenevolentAI SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 43874900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €103.00K | 0.11% |
| Other Components | €613.58 Million | 650.86% |
| Total Equity | €94.27 Million | 100.00% |
BenevolentAI SA Competitors by Market Cap
The table below lists competitors of BenevolentAI SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Scandinavian Investment Group A/S
CO:SIG
|
$9.51 Million |
|
Vince Holding Corp
NYSE:VNCE
|
$9.51 Million |
|
Team Young Advanced Technology Co Ltd
TWO:5345
|
$9.51 Million |
|
Janel Corp
PINK:JANL
|
$9.51 Million |
|
AEON Biopharma, Inc.
NYSE MKT:AEON
|
$9.51 Million |
|
Cannindah Resources Ltd
AU:CAE
|
$9.51 Million |
|
THUNDERFUL GROUP SK
F:8JH
|
$9.50 Million |
|
Coloray International Investment Co. Ltd
KQ:900310
|
$9.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BenevolentAI SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 153,999,000 to 94,271,000, a change of -59,728,000 (-38.8%).
- Net loss of 63,317,000 reduced equity.
- Other factors increased equity by 3,589,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-63.32 Million | -67.16% |
| Other Changes | €3.59 Million | +3.81% |
| Total Change | €- | -38.78% |
Book Value vs Market Value Analysis
This analysis compares BenevolentAI SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.11x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | €0.55 | €0.08 | x |
| 2019-12-31 | €0.86 | €0.08 | x |
| 2020-12-31 | €0.84 | €0.08 | x |
| 2021-12-31 | €0.43 | €0.08 | x |
| 2022-12-31 | €1.41 | €0.08 | x |
| 2023-12-31 | €0.76 | €0.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BenevolentAI SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -67.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -863.69%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.31x
- Recent ROE (-67.16%) is above the historical average (-71.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -33.55% | -393.79% | 0.08x | 1.12x | €-34.89 Million |
| 2019 | -38.58% | -1043.53% | 0.03x | 1.21x | €-60.98 Million |
| 2020 | -45.15% | -801.56% | 0.05x | 1.21x | €-67.63 Million |
| 2021 | -137.43% | -1869.92% | 0.05x | 1.47x | €-92.78 Million |
| 2022 | -106.45% | -1552.35% | 0.06x | 1.21x | €-179.33 Million |
| 2023 | -67.16% | -863.69% | 0.06x | 1.31x | €-72.74 Million |
Industry Comparison
This section compares BenevolentAI SA's net assets metrics with peer companies in the Biotechnology industry.
No peer company data available for comparison.